Other
2028
Merck & Co. 2028 increased by 22.7% to $2.70B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.7%, from $2.20B to $2.70B. Over 5 years (FY 2020 to FY 2025), 2028 shows an upward trend with a 3.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026
How to read this metric
A predictable and manageable maturity schedule indicates strong financial planning and lower risk of default.
Detailed definition
This represents the specific portion of long-term debt principal scheduled for repayment during the 2028 fiscal year. It...
Peer comparison
Most large-cap industrial companies maintain a balanced maturity schedule to avoid concentrated repayment pressure.
Metric ID:
other_long_term_debt_maturities_repayments_of_principal__62d406Historical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.70B | $1.30B | $2.50B | $2.20B | $2.70B |
| QoQ Change | — | -23.5% | +92.3% | -12.0% | +22.7% |
| YoY Change | — | -23.5% | +92.3% | -12.0% | +22.7% |
Range$1.30B – $2.70B
CAGR+58.8%
Avg YoY Growth+19.9%
Median YoY Growth+5.4%
2028 at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s 2028?
- Merck & Co. (MRK) reported 2028 of $2.70B in Q4 2025.
- How has Merck & Co.'s 2028 changed year-over-year?
- Merck & Co.'s 2028 increased by 22.7% year-over-year, from $2.20B to $2.70B.
- What is the long-term trend for Merck & Co.'s 2028?
- Over 5 years (2020 to 2025), Merck & Co.'s 2028 has grown at a 3.3% compound annual growth rate (CAGR), from $2.30B to $2.70B.
- What does 2028 mean?
- The amount of long-term debt principal that must be repaid in 2028.